Wa'el Hashad
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 16h05 HE | Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Nataliya Agafonova
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
28 juil. 2024 16h51 HE | Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Immatics Final logo (R)_white_background.png
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
24 oct. 2023 07h00 HE | https://immatics.com/
  RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer typesRegulatory activities...
Autolus-Logo_Bright_Blue-–-RGB.png
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
25 avr. 2022 07h01 HE | Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Voyager Therapeutics Logo.jpg
Voyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease
21 juin 2018 07h03 HE | Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., June 21, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...